Clinical utility of the C ‐reactive protein:albumin ratio in non‐small cell lung cancer patients treated with nivolumab

ConclusionsFor second ‐line nivolumab therapy, evaluation of baseline CAR and subsequent changes in CAR may be predictive of therapeutic response to nivolumab and long‐term survival in NSCLC patients.Key pointsSignificant findings of the studyThe baseline value of C ‐reactive protein:albumin ratio was significantly associated with one‐year mortality and overall survival in non‐small cell lung cancer patients treated with nivolumab.What this study addsTime ‐series change of C‐reactive protein:albumin ratio may be useful for predicting the treatment efficacy in patients treated with nivolumab.

Source: Thoracic Cancer - January 12, 2021 Category: Cancer & Oncology Authors: Taisuke Araki, Kazunari Tateishi, Kei Sonehara, Shuko Hirota, Masamichi Komatsu, Manabu Yamamoto, Shintaro Kanda, Hiroshi Kuraishi, Masayuki Hanaoka, Tomonobu Koizumi Tags: ORIGINAL ARTICLE Source Type: research